Rxwire
In the news · 48h FDA 38 Eli Lilly 17 Roche 9 Merck & Co. (MSD) 7 Johnson & Johnson 4 AbbVie 3 AstraZeneca 3 Daiichi Sankyo 2
Deals & business · first seen 2h ago, updated 2h ago

RNAi drug specialist ADARx raises $446M IPO

1 outlet

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Summary from BioPharma Dive.

Coverage 1 article · 1 outlet

  1. BioPharma Dive
    RNAi drug specialist ADARx raises $446M IPO